Literature DB >> 15136238

Additional transplantation of ex vivo generated megakaryocytic cells after high-dose chemotherapy.

Stefan Scheding, Markus Bergmannn, Gisa Rathke, Wichard Vogel, Wolfram Brugger, Lothar Kanz.   

Abstract

The additional transplantation of ex vivo generated hematopoietic (post)-progenitor cells represents a possible approach to ameliorate high-dose chemotherapy induced cytopenia. We investigated the feasibility of the large-scale expansion and transplantation of autologous megakaryocytic cells in four patients with advanced solid tumors. Up to 1,460x10(6) ex vivo generated cells were administered without adverse effects but no clear cut effect on platelet recovery was observed.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15136238

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  6 in total

1.  Bone marrow niche-inspired, multiphase expansion of megakaryocytic progenitors with high polyploidization potential.

Authors:  Swapna Panuganti; Eleftherios T Papoutsakis; William M Miller
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

2.  Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors.

Authors:  Dorothee Eicke; Anja Baigger; Kai Schulze; Sharissa L Latham; Caroline Halloin; Robert Zweigerdt; Carlos A Guzman; Rainer Blasczyk; Constança Figueiredo
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

3.  Enabling Large-Scale Ex Vivo Production of Megakaryocytes from CD34+ Cells Using Gas-Permeable Surfaces.

Authors:  Andres F Martinez; William M Miller
Journal:  Stem Cells Transl Med       Date:  2019-03-08       Impact factor: 6.940

4.  Good Manufacturing Practice-Grade of Megakaryocytes Produced by a Novel Ex Vivo Culturing Platform.

Authors:  Xin Guan; Lan Wang; Hanlu Wang; Huihui Wang; Wei Dai; Yongping Jiang
Journal:  Clin Transl Sci       Date:  2020-10-08       Impact factor: 4.689

5.  Infusion of megakaryocytic progenitor products generated from cord blood hematopoietic stem/progenitor cells: results of the phase 1 study.

Authors:  Jiafei Xi; Honghu Zhu; Daqing Liu; Xue Nan; Wen Zheng; Kaiyan Liu; Wei Shi; Lin Chen; Yang Lv; Fang Yan; Yanhua Li; Xiaoyan Xie; Yunfang Wang; Wen Yue; Xin Xu; Xiaofei Wei; Jun Zhu; Xiaojun Huang; Xuetao Pei
Journal:  PLoS One       Date:  2013-02-04       Impact factor: 3.240

6.  Optimal ex vivo expansion of neutrophils from PBSC CD34+ cells by a combination of SCF, Flt3-L and G-CSF and its inhibition by further addition of TPO.

Authors:  Olga Tura; G Robin Barclay; Huw Roddie; John Davies; Marc L Turner
Journal:  J Transl Med       Date:  2007-10-30       Impact factor: 5.531
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.